Results 71 to 80 of about 10,900 (261)

Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study

Frontiers in Pharmacology, 2020
ObjectiveCurrent prevention and/or treatment options for respiratory syncytial virus (RSV) infections are limited as no vaccine is available. Prophylaxis with palivizumab is very expensive and requires multiple intramuscular injections over the RSV ...
Anushi E. Rajapaksa, Anushi E. Rajapaksa, Anushi E. Rajapaksa, Lien Anh Ha Do, Lien Anh Ha Do, Darren Suryawijaya Ong, Darren Suryawijaya Ong, Magdy Sourial, Duncan Veysey, Richard Beare, Richard Beare, William Hughes, William Yang, Robert J. Bischof, Robert J. Bischof, Amarin McDonnell, Peter Eu, Leslie Y. Yeo, Paul V. Licciardi, Paul V. Licciardi, Edward K. Mulholland, Edward K. Mulholland, Edward K. Mulholland   +22 more
doaj   +1 more source

Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).

Vaccine
BACKGROUND Nirsevimab is an extended half-life monoclonal antibody (mAb) licensed for the prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract disease in neonates, infants and medically vulnerable children.
K. Tuffy, Bahar Ahani, Joseph B. Domachowske, Kenji Furuno, Hong-meng Ji, S. Madhi, V. S. Mankad, U. W. Hamrén, T. Villafana, Yingyi Wang, Elizabeth J. Kelly, Deidre Wilkins   +11 more
semanticscholar   +1 more source

Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals

medRxiv, 2021
Palivizumab is a monoclonal antibody which can prevent infection with respiratory syncytial virus (RSV). Due to its high cost, it is recommended for high‐risk infants only.
A. Zylbersztejn, Ofran Almossawi, Nikesh Gudka, Daniel Tompsett, B. D. De Stavola, J. Standing, R. Smyth, P. Hardelid   +7 more
semanticscholar   +1 more source

Predictive Value of Modified Lung Ultrasound Score for Late Respiratory Diseases in Premature Infants: A Retrospective Cohort Analysis

Journal of Clinical Ultrasound, Volume 54, Issue 4, Page 915-923, May 2026.
This study is to assess the predictive value of the modified lung ultrasound score (mLUS) for late respiratory diseases in premature infants born before 32 weeks of gestation. It is recommended that the use of mLUS scoring be promoted in clinical practice for the early screening of high‐risk preterm infants.
Shuang Zheng, Yang Zhang, Yanan Gao, Huifen Chen, Sudan Liu   +4 more
wiley   +1 more source

Respiratory Syncytial Virus (RSV): A Comprehensive Overview From Basic Biology to Clinical Prevention and Control

Medicinal Research Reviews, Volume 46, Issue 3, Page 672-712, May 2026.
ABSTRACT Respiratory syncytial virus (RSV) is a common virus that causes respiratory infections, posing a serious threat, particularly to infants, the elderly, and individuals with compromised immune systems. As the leading cause of lower respiratory tract infections (LRTIs) in infants, RSV is responsible for millions of cases worldwide each year.
Jie Shi, Xiya Huang, Chunjun Ye, Yishan Lu, Yanyan Liu, Yuquan Wei, Xiawei Wei   +6 more
wiley   +1 more source

Universal palivizumab prophylaxis for children with Down syndrome in Japan: analysis with interrupted time-series

Human Vaccines & Immunotherapeutics, 2021
Down syndrome (DS) is an independent risk factor for severe respiratory syncytial virus (RSV) infection. Palivizumab – passive immunization for RSV – is the only pharmacological measure for preventing severe disease.
Masato Takeuchi, Koji Kawakami
doaj   +1 more source

A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom / [PDF]

, 2013
Background: Respiratory syncytial virus (RSV) is a common cause of respiratory infection that is highly prevalent in infants. Severe cases of RSV infection require hospitalisation; this is most likely to occur in infant populations at high risk.
Bentley, Anthony, Büsch, Katharina, Filipovic, Ivana, Gooch, Katherine   +3 more
core   +1 more source

Impact of Palivizumab in Preventing Severe Acute Lower Respiratory Infection in Moderate-to-Late Preterm Infants: A Nationwide Cohort Study

Journal of Korean medical science
Background Respiratory syncytial virus (RSV) prophylaxis using palivizumab effectively reduces RSV-associated morbidity in preterm infants. In Korea, national insurance coverage for palivizumab was implemented in October 2016 for moderate-to-late preterm
Seungyeon Kim, Y. J. Choe, Saram Lee, J. Heo   +3 more
semanticscholar   +1 more source

The Development of Global Genomic Surveillance of Respiratory Syncytial Virus: Insights From 25 Project Countries, 2019–2023

Influenza and Other Respiratory Viruses, Volume 20, Issue 3, March 2026.
ABSTRACT Background From 2016 to 2018, the World Health Organization (WHO) initiated a global RSV surveillance pilot program in 14 countries, expanding to 25 countries from 2019 to 2023. As part of this, a sequencing program was introduced to improve the understanding of RSV global genetic diversity prior to and following the introduction of ...
Obadiah Kenji, Fernando Motta, Thomas Williams, Nicole Wolter, Ian G. Barr, Clyde Dapat, Maria Zambon, Lucy Mosscrop, Mei Shang, Sergejs Nikisins, Siddhivinayak Hirve, Wenqing Zhang, the WHO RSV Surveillance Group   +12 more
wiley   +1 more source

The Danish National Prescription Registry in studies of a biological pharmaceutical: palivizumab – validation against two external data sources

Clinical Epidemiology, 2015
Ann Haerskjold,1,2 Lonny Henriksen,2 Susanne Way,1 Mikkel Malham,3 Jesper Hallas,4 Lars Pedersen,5 Lone Graff Stensballe1 1The Child and Adolescent Clinic 4072, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; 2The Research Unit Women&#
Haerskjold A, Henriksen L, Way S, Malham M, Hallas J, Pedersen L, Stensballe LG   +6 more
doaj